Anaplastic glioma (Q39246821)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Anaplastic glioma	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

10 September 2017

Anaplastic glioma (English)

1 reference

Europe PubMed Central

10 September 2017

Nina A. Paleologos

1

object named as

Nina A Paleologos

1 reference

Europe PubMed Central

10 September 2017

author name string

Ryan T Merrell

2

1 reference

Europe PubMed Central

10 September 2017

publication date

1 August 2012

1 reference

Europe PubMed Central

10 September 2017

Current treatment options in neurology

1 reference

Europe PubMed Central

10 September 2017

14

1 reference

Europe PubMed Central

10 September 2017

381-390

1 reference

Europe PubMed Central

10 September 2017

4

1 reference

Europe PubMed Central

10 September 2017

https://scigraph.springernature.com/pub.10.1007/s11940-012-0177-6

0 references

Malignant gliomas in adults

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

The results of radiotherapy for ependymomas: the Mayo Clinic experience.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Molecular predictors in glioblastoma: toward personalized therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Identification of novel biomarkers in pediatric primitive neuroectodermal tumors and ependymomas by proteome-wide analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

A PDGFRA promoter polymorphism, which disrupts the binding of ZNF148, is associated with primitive neuroectodermal tumours and ependymomas

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

alpha(v)beta(3) Integrin in central nervous system tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Expression of cyclo-oxygenase-2 in ependymal tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Epidermal growth factor receptors on ependymomas and other brain tumors

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

O6-Methylguanine-DNA-methyltransferase in recurring anaplastic ependymomas: PCR and immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

An extent of resection threshold for newly diagnosed glioblastomas

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Supratentorial ependymomas: prognostic factors and outcome analysis in a retrospective series of 46 adult patients

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Treatment of recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

A case report of a recurrent intracranial ependymoma treated with temozolomide in remission 10 years after completing chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0177-6

21 January 2018

A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22665140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22665140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22665140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of prophylactic spinal irradiation in localized intracranial ependymoma intracranial ependymoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22665140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22665140

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11940-012-0177-6

1 reference

Europe PubMed Central

10 September 2017

1 reference

Europe PubMed Central

10 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39246821&oldid=1953779081"